Semaglutide formulations compared: what the data actually shows

What did @myrajoinmochi actually say?

The creator argued that Rybelsus (oral semaglutide) and injectable semaglutide produce "pretty similar" weight loss results once you account for the lifestyle support differences between their clinical trials. They pointed out that Rybelsus patients lost about 5% body weight at 26 weeks while injectable semaglutide patients lost about 10%, but the injectable group had dietitian visits, a 500-calorie daily deficit, and 150 minutes of weekly exercise baked into the protocol. They also claimed oral semaglutide gets less industry investment because government insurers can negotiate prices sooner, after three years instead of nine.

These are genuinely interesting points, not the usual TikTok "lose weight fast" content. But the conclusion, that the two formulations are roughly equivalent when you strip out lifestyle differences, requires more scrutiny than a single comparison of placebo-subtracted effect sizes.

Does the science back this up?

Partially, but the creator is doing something statistically shaky: using placebo-corrected differences from two separate trials to argue equivalence. That is not how drug comparisons work, and the trials were not designed to be compared head-to-head.

The Rybelsus weight data the creator references comes from the PIONEER trials. PIONEER 1, published by Aroda et al. (2019, Diabetes Care), showed oral semaglutide 14 mg achieved roughly 4.1 kg weight loss versus 0.5 kg for placebo over 26 weeks, a net difference of about 3.6 kg. The injectable semaglutide data for weight loss, particularly at the higher 2.4 mg weekly dose approved as Wegovy, comes from the STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine), which showed 14.9% mean body weight reduction versus 2.4% for placebo over 68 weeks. That is a much longer trial, a higher dose, and a different patient population. Comparing placebo-subtracted numbers across these two trials as a proxy for head-to-head equivalence is not scientifically sound methodology.

What did they get wrong (or right)?

They got the lifestyle imbalance point right. The STEP trials did include structured lifestyle intervention that the PIONEER trials largely did not, and that matters. Credit where it is due.

But a few things deserve pushback. First, the claim that the weight loss is "actually pretty similar" after accounting for lifestyle differences is speculation, not a finding from any published analysis. No peer-reviewed paper has formally modeled what Rybelsus results would look like with equivalent lifestyle support, or vice versa. Second, the creator says Rybelsus "only" had a 26-week study, which undersells the fuller PIONEER program. PIONEER 4, for instance, ran 52 weeks and compared oral semaglutide 14 mg directly to injectable liraglutide 1.2 mg, not to higher-dose injectable semaglutide. Third, the patent and pricing claim, that oral drugs face government price negotiation after three years instead of nine, is a reference to the Inflation Reduction Act small-molecule versus biologic distinction. This is real policy, but the framing oversimplifies a complex regulatory situation.

What should you actually know?

Injectable semaglutide at the doses used in Wegovy (up to 2.4 mg weekly) is currently the better-studied and more potent option for weight loss. That is not a pharmaceutical industry talking point, it is what the trial data shows. The STEP 1 trial (Wilding et al., 2021, NEJM) enrolled over 1,900 adults with obesity and demonstrated nearly 15% weight loss over 68 weeks. No equivalent long-term, high-dose weight loss trial exists for oral semaglutide at its currently approved 14 mg ceiling.

That said, oral semaglutide is a legitimate option for people who cannot or will not use injections, and the gastrointestinal side effect profile does appear more favorable. A 2022 network meta-analysis by Shi et al. (Frontiers in Endocrinology) found oral semaglutide competitive with some other GLP-1 agents but not with high-dose injectable semaglutide for weight outcomes.

• Rybelsus is FDA-approved for type 2 diabetes, not weight loss. Using it for weight loss is off-label prescribing.
• Wegovy (2.4 mg injectable semaglutide) is specifically FDA-approved for chronic weight management.
• Absorption of oral semaglutide is highly sensitive to food, water, and timing, which affects real-world effectiveness compared to controlled trial conditions.
• The Inflation Reduction Act does allow faster price negotiation for small-molecule drugs, which includes oral semaglutide. The creator's concern about industry incentives is legitimate, even if the three-versus-nine-year framing is a simplification.

The bottom line

This creator is asking a smarter question than most GLP-1 TikTok content. But "smarter question" is not the same as "correct answer." Comparing placebo-subtracted weight loss numbers across trials with different durations, doses, populations, and lifestyle protocols is not a valid method for claiming equivalence. Injectable semaglutide at higher doses has meaningfully stronger weight loss data. That may change as oral semaglutide research matures, and the pricing dynamics the creator raises are a real reason to watch this space carefully.